KPL-387
Recurrent Pericarditis
Phase 2/3Recruiting (KPL-387-C211)
Key Facts
Indication
Recurrent Pericarditis
Phase
Phase 2/3
Status
Recruiting (KPL-387-C211)
Company
About Kiniksa Pharmaceuticals
Kiniksa Pharmaceuticals is a publicly traded biopharma focused on immune modulation for cardiovascular and autoimmune diseases with high unmet need. Founded in 2015, its key achievement is the FDA approval and commercialization of ARCALYST® (rilonacept), the first and only therapy for recurrent pericarditis, providing a foundational revenue stream. The company's strategy leverages strategic in-licensing and targeted development of biologics with strong biologic rationale, building a balanced portfolio that spans commercial and clinical-stage assets. This approach, led by a seasoned team with a proven track record in rare diseases, aims to deliver differentiated therapies rapidly.
View full company profileTherapeutic Areas
Other Recurrent Pericarditis Drugs
| Drug | Company | Phase |
|---|---|---|
| ARCALYST (rilonacept) | Kiniksa Pharmaceuticals | Commercial |
| CardiolRx™ | Cardiol Therapeutics | Phase II |